Gene expression profiling of CD34+ cells in patients with the 5q- syndrome
- PMID: 17916100
- DOI: 10.1111/j.1365-2141.2007.06833.x
Gene expression profiling of CD34+ cells in patients with the 5q- syndrome
Abstract
The transcriptome of the CD34+ cells was determined in a group of 10 patients with the 5q- syndrome using a comprehensive array platform, and was compared with the transcriptome of CD34+ cells from 16 healthy control subjects and 14 patients with refractory anaemia and a normal karyotype. The majority of the genes assigned to the commonly deleted region (CDR) of the 5q- syndrome at 5q31-q32 showed a reduction in expression levels in patients with the 5q- syndrome, consistent with the loss of one allele. Candidate genes showing haploinsufficiency in the 5q- syndrome included the tumour suppressor gene SPARC and RPS14, a component of the 40S ribosomal subunit. Two genes mapping to the CDR, RBM22 and CSNK1A1, showed a >50% reduction in gene expression, consistent with the downregulation of the remaining allele. This study identified several significantly deregulated gene pathways in patients with the 5q- syndrome and gene pathway analysis data supports the proposal that SPARC may play a role in the pathogenesis of the 5q- syndrome. This study suggests that several of the genes mapping to the CDR of the 5q- syndrome play a role in the pathogenesis of this disorder.
Similar articles
-
Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation.Nat Med. 2007 Jan;13(1):78-83. doi: 10.1038/nm1512. Epub 2006 Dec 10. Nat Med. 2007. PMID: 17159988
-
Transcription mapping of the 5q- syndrome critical region: cloning of two novel genes and sequencing, expression, and mapping of a further six novel cDNAs.Genomics. 2000 May 15;66(1):26-34. doi: 10.1006/geno.2000.6193. Genomics. 2000. PMID: 10843801
-
Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q-.Haematologica. 2008 Jul;93(7):1001-8. doi: 10.3324/haematol.13012. Haematologica. 2008. PMID: 18591625
-
Van-den Berghe's 5q- syndrome in 2008.Br J Haematol. 2009 Jan;144(2):157-68. doi: 10.1111/j.1365-2141.2008.07447.x. Epub 2008 Nov 7. Br J Haematol. 2009. PMID: 19016715 Review.
-
5q- myelodysplastic syndromes: chromosome 5q genes direct a tumor-suppression network sensing actin dynamics.Oncogene. 2009 Oct 1;28(39):3429-41. doi: 10.1038/onc.2009.207. Epub 2009 Jul 13. Oncogene. 2009. PMID: 19597464 Review.
Cited by
-
Haploinsufficiency of RPS14 in 5q- syndrome is associated with deregulation of ribosomal- and translation-related genes.Br J Haematol. 2008 Jul;142(1):57-64. doi: 10.1111/j.1365-2141.2008.07178.x. Epub 2008 May 8. Br J Haematol. 2008. PMID: 18477045 Free PMC article.
-
Molecular dissection of the 5q deletion in myelodysplastic syndrome.Semin Oncol. 2011 Oct;38(5):621-6. doi: 10.1053/j.seminoncol.2011.04.010. Semin Oncol. 2011. PMID: 21943668 Free PMC article. Review.
-
Loss of Tifab, a del(5q) MDS gene, alters hematopoiesis through derepression of Toll-like receptor-TRAF6 signaling.J Exp Med. 2015 Oct 19;212(11):1967-85. doi: 10.1084/jem.20141898. Epub 2015 Oct 12. J Exp Med. 2015. PMID: 26458771 Free PMC article.
-
The biology of myelodysplastic syndromes: unity despite heterogeneity.Hematol Rep. 2010 Jan 26;2(1):e4. doi: 10.4081/hr.2010.e4. Epub 2010 Jun 23. Hematol Rep. 2010. PMID: 22184517 Free PMC article.
-
Reduced ribosomal protein gene dosage and p53 activation in low-risk myelodysplastic syndrome.Blood. 2011 Sep 29;118(13):3622-33. doi: 10.1182/blood-2010-11-318584. Epub 2011 Jul 25. Blood. 2011. PMID: 21788341 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
